{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:37:12Z","timestamp":1782563832506,"version":"3.54.5"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T00:00:00Z","timestamp":1428883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0003693","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T18:21:03Z","timestamp":1428949263000},"page":"e0003693","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["A DNA Vaccine against Yellow Fever Virus: Development and Evaluation"],"prefix":"10.1371","volume":"9","author":[{"given":"Milton","family":"Maciel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bia da Silva Pereira","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marli Ten\u00f3rio","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia Archer","family":"da Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kl\u00e9cia Mar\u00edlia Soares de Melo","family":"Cassemiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita de C\u00e1ssia Carvalho","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina C\u00e9lia Bressan Queiroz","family":"de Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Galler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos da Silva","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Thomas","family":"August","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto T. A.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Dhalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,4,13]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.antiviral.2012.12.002","article-title":"Experimental therapies for yellow fever","volume":"97","author":"JG Julander","year":"2013","journal-title":"Antiviral Res"},{"key":"ref2","article-title":"Global health situation and projections\u2014-estimates","year":"1992"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"TP Monath","year":"2005","journal-title":"Hum Vaccin"},{"issue":"6","key":"ref4","first-page":"895","article-title":"Persistence of neutralizing antibody 30\u201335 years after immunization with 17D yellow fever vaccine","volume":"59","author":"JD Poland","year":"1981","journal-title":"Bull World Health Organ"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B","article-title":"Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection","volume":"56","author":"B Reinhardt","year":"1998","journal-title":"J Med Virol"},{"issue":"14","key":"ref6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2013.01.054","article-title":"Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010","volume":"31","author":"JG Breugelmans","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","DOI":"10.4161\/hv.22714","article-title":"Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more","volume":"9","author":"KT Miyaji","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"ref8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.trstmh.2012.04.002","article-title":"Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali","volume":"106","author":"M Sidibe","year":"2012","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/157488611797579258","article-title":"Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review","volume":"6","author":"RE Thomas","year":"2011","journal-title":"Curr Drug Saf"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"TP Monath","year":"2002","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11908-996-0005-9","article-title":"Current Assessment of Yellow Fever and Yellow Fever Vaccine","volume":"6","author":"A Lefeuvre","year":"2004","journal-title":"Curr Infect Dis Rep"},{"issue":"9276","key":"ref12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Brazilian Yellow Fever Vaccine Evaluation. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases","volume":"358","author":"PF Vasconcelos","year":"2001","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0065-3527(08)60367-X","article-title":"DNA vaccines: a review","volume":"54","author":"PJ Lewis","year":"1999","journal-title":"Adv Virus Res"},{"issue":"2\u20133","key":"ref14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"L Li","year":"2012","journal-title":"J Biotechnol"},{"issue":"5","key":"ref15","first-page":"549","article-title":"DNA vaccines: basic mechanism and immune responses (Review)","volume":"4","author":"HL Robinson","year":"1999","journal-title":"Int J Mol Med"},{"issue":"4\u20136","key":"ref16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000053988","article-title":"Update on antiviral DNA vaccine research (1998\u20132000)","volume":"43","author":"J Schultz","year":"2000","journal-title":"Intervirology"},{"issue":"17\u201318","key":"ref17","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/S0264-410X(03)00009-4","article-title":"Dengue 2 PreM-E\/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies","volume":"21","author":"Y Lu","year":"2003","journal-title":"Vaccine"},{"issue":"22","key":"ref18","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/S0264-410X(99)00570-8","article-title":"Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein","volume":"18","author":"K Raviprakash","year":"2000","journal-title":"Vaccine"},{"issue":"25\u201326","key":"ref19","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1016\/S0264-410X(03)00376-1","article-title":"Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice","volume":"21","author":"E Konishi","year":"2003","journal-title":"Vaccine"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1128\/JVI.72.6.4925-4930.1998","article-title":"Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes","volume":"72","author":"E Konishi","year":"1998","journal-title":"J Virol"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.micinf.2006.06.010","article-title":"Development of an effective Japanese encephalitis virus-specific DNA vaccine","volume":"8","author":"CJ Wu","year":"2006","journal-title":"Microbes Infect"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virol.2004.11.022","article-title":"West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II compartment, and enhanced neutralizing antibody response","volume":"332","author":"A Anwar","year":"2005","journal-title":"Virology"},{"issue":"11\u201312","key":"ref23","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0264-410X(99)00376-X","article-title":"A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice","volume":"18","author":"E Konishi","year":"2000","journal-title":"Vaccine"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/viro.2001.1136","article-title":"Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF","volume":"290","author":"K Raviprakash","year":"2001","journal-title":"Virology"},{"issue":"39","key":"ref25","doi-asserted-by":"crossref","first-page":"37926","DOI":"10.1074\/jbc.M303336200","article-title":"HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses","volume":"278","author":"ET Marques Jr","year":"2003","journal-title":"J Biol Chem"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2567.2004.01823.x","article-title":"DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response","volume":"112","author":"LB de Arruda","year":"2004","journal-title":"Immunology"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1083\/jcb.102.5.1593","article-title":"Lysosomal membrane dynamics: structure and interorganellar movement of a major lysosomal membrane glycoprotein","volume":"102","author":"J Lippincott-Schwartz","year":"1986","journal-title":"J Cell Biol"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.4049\/jimmunol.162.2.1150","article-title":"Involvement of MIIC-like late endosomes in B cell receptor-mediated antigen processing in murine B cells","volume":"162","author":"JR Drake","year":"1999","journal-title":"J Immunol"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1083\/jcb.139.3.639","article-title":"Major histocompatibility complex class II compartments in human and mouse B lymphoblasts represent conventional endocytic compartments","volume":"139","author":"MJ Kleijmeer","year":"1997","journal-title":"J Cell Biol"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.4049\/jimmunol.177.4.2265","article-title":"Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes","volume":"177","author":"LB Arruda","year":"2006","journal-title":"J Immunol"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.virol.2004.02.025","article-title":"Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag\/LAMP DNA vaccine chimera","volume":"323","author":"P Chikhlikar","year":"2004","journal-title":"Virology"},{"issue":"9\u201310","key":"ref32","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0264-410X(98)00320-X","article-title":"Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine","volume":"17","author":"I Stefano","year":"1999","journal-title":"Vaccine"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.virol.2008.04.043","article-title":"Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB\/c (H2d) mice model","volume":"378","author":"M. Maciel Jr","year":"2008","journal-title":"Virology"},{"key":"ref34","unstructured":"WHO. Requirements for the production and control of yellow fever vaccine. (Requirements for Biological Substances No. 3.) In: WHO Expert Committee on Biological Standardization. Forty-sixth report. Geneva, World Health Organization, 1998, Annex 2 (WHO Technical Report Series, No. 872)."},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1099\/0022-1317-67-4-631","article-title":"Comparison of neurovirulence of different strains of yellow fever virus in mice","volume":"67","author":"AD Barrett","year":"1986","journal-title":"J Gen Virol"},{"key":"ref36","unstructured":"Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002;51(RR-17): 1\u201311; quiz CE11-14."},{"issue":"9","key":"ref37","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.4049\/jimmunol.156.9.3151","article-title":"Peptide-based, but not whole protein, vaccines elicit immunity to HER-2\/neu, oncogenic self-protein","volume":"156","author":"ML Disis","year":"1996","journal-title":"J Immunol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1146\/annurev.iy.11.040193.003501","article-title":"Dominance and crypticity of T cell antigenic determinants","volume":"11","author":"EE Sercarz","journal-title":"Annu Rev Immunol"},{"issue":"17","key":"ref39","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1128\/JVI.74.17.8094-8101.2000","article-title":"Chimeric yellow fever\/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response","volume":"74","author":"RG van Der Most","year":"2000","journal-title":"J Virol"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1099\/0022-1317-67-2-229","article-title":"Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses","volume":"67","author":"MW Brandriss","year":"1986","journal-title":"J Gen Virol"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.4049\/jimmunol.135.4.2805","article-title":"Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48","volume":"135","author":"JJ Schlesinger","year":"1985","journal-title":"J Immunol"},{"issue":"8","key":"ref42","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1099\/0022-1317-71-8-1697","article-title":"Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b","volume":"71","author":"JR Putnak","year":"1990","journal-title":"J Gen Virol"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1099\/0022-1317-72-11-2811","article-title":"Recombinant baculoviruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice","volume":"72","author":"P Despres","year":"1991","journal-title":"J Gen Virol"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0042-6822(92)90317-I","article-title":"Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis","volume":"187","author":"S Pincus","year":"1992","journal-title":"Virology"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0003693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T12:09:07Z","timestamp":1691582947000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0003693"}},"subtitle":[],"editor":[{"given":"Kenji","family":"Hirayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,13]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0003693","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,13]]}}}